phase 2/UK: The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer - Full Text View - ClinicalTrials.gov

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer - Full Text View - ClinicalTrials.gov

The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer (TRIOC)

This study is not yet open for participant recruitment.

Verified March 2012 by University College, London

First Received on March 14, 2012.   Last Updated on March 27, 2012   History of Changes

Sponsor:	University College, London
Collaborators:	Oxford BioMedica Cancer Research UK
Information provided by (Responsible Party):	University College, London
ClinicalTrials.gov Identifier:	NCT01556841

  Purpose

The purpose of this trial is to assess the effectiveness of TroVax® compared to placebo in extending the time to progression in patients with asymptomatic relapsed platinum resistant ovarian, fallopian tube or primary peritoneal cancer.The trial will also look at overall survival times and quality of life.

Incidental Adnexal Masses Detected at Low-Dose Unenhanced CT in Asymptomatic Women Age 50 and Older: Implications for Clinical Management and Ovarian Cancer Screening - Radiology (abstract)

 Results: One hundred eighteen women (mean age, 56.2 years), representing 4.1% of the screening cohort, had an indeterminate adnexal mass (108 unilateral, 10 bilateral; mean size, 4.1 cm) at prospective CT interpretation......No ovarian cancers were prospectively identified, although four cases of ovarian cancer developed subsequent to a negative adnexal finding at CT examination during a 15–44-month interval among the remaining 2751 women. cont'd

 Materials and Methods: This study was institutional review board approved and HIPAA compliant. Informed consent was waived. The fate of indeterminate adnexal lesions identified at unenhanced CT in 2869 consecutive women (mean age, 57.2 years; age range, 50–97 years) undergoing colonography screening between April 2004 and December 2008 was evaluated.
Conclusion:
Incidental indeterminate adnexal lesions were relatively common at unenhanced CT (4.1%), but subsequent work-up revealed no ovarian cancers. Furthermore, a normal finding at CT was not protective against short-term development of ovarian cancer. More sophisticated risk factor assessment is needed to identify women at higher risk.